News | June 01, 2009

Generex Presents Positive Results of Phase 1 Prostate Cancer Vaccine Trial at ASCO

June 1, 2009 - Generex Biotechnology Corporation announced today that the results of a recently completed Phase I trial in prostate cancer patients of the novel immunotherapeutic peptide AE37 were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Orlando, Fla., from May 29 to June 2, 2009.

The studies were conducted in Athens, Greece under the direction of medical doctor Constantin Baxevanis. The immunotherapeutic peptide AE37 is being developed by Antigen Express Inc., a wholly-owned subsidiary of Generex, for multiple cancer indications.

The study, entitled "Results from the First Phase I Clinical Study of the Novel Ii-Key/HER-2/neu (776-790) Hybrid Peptide Vaccine in Patients with Prostate Cancer," reports on both the safety and immunological response to the vaccine in patients. The trial demonstrated that the vaccine is safe, well tolerated and produces the desired immunological response in patients. The results of this study are consistent with those of prior clinical trials of AE37 in patients with breast cancer. AE37 is currently the subject of a randomized phase II clinical trial in patients with node positive or high risk node negative breast cancer as well as an additional phase I trial wherein it is being studied in combination with another immunotherapeutic peptide.

For more information:

Related Content

Varian Purchasing Embolic Bead Assets from Boston Scientific
News | Interventional Radiology | July 03, 2019
Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable...
FDA Approves Exablate Neuro for Tremor-Dominant Parkinson's Treatment
Technology | Focused Ultrasound Therapy | December 21, 2018
Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
News | Radiation Dose Management | September 24, 2018
AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
MR-HIFU, ThermoDox, combination therapy, recurrent childhood tumors, Celsion, Children's National Health System, Phase I clinical study
News | Oncology Related Products | December 19, 2016
December 19, 2016 — Children’s National Health System and Celsion Corp.
News | Clinical Decision Support | October 27, 2016
October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use
contrast-enhanced ultrasound, CEUS, liver cancer, hepatocellular carcinoma, study, Advances in Contrast Ultrasound conference, ICUS
News | Ultrasound Imaging | September 12, 2016
September 12, 2016 — Tiny microbubbles are being used to more effectively...
cardio-oncology, echo strain assessment, echoinsight, epsilon

Epsilon's EchoInsight software helps analyze cardiac function by evaluating wall motion strain. 

Feature | Cardio-oncology | May 13, 2016 | Dave Fornell
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat